223 related articles for article (PubMed ID: 32755567)
1. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.
Liu Y; Ferguson FM; Li L; Kuljanin M; Mills CE; Subramanian K; Harshbarger W; Gondi S; Wang J; Sorger PK; Mancias JD; Gray NS; Westover KD
Cell Chem Biol; 2020 Oct; 27(10):1229-1240.e4. PubMed ID: 32755567
[TBL] [Abstract][Full Text] [Related]
2. Autoregulatory control of microtubule binding in doublecortin-like kinase 1.
Agulto RL; Rogers MM; Tan TC; Ramkumar A; Downing AM; Bodin H; Castro J; Nowakowski DW; Ori-McKenney KM
Elife; 2021 Jul; 10():. PubMed ID: 34310279
[TBL] [Abstract][Full Text] [Related]
3. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
4. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1.
Patel O; Dai W; Mentzel M; Griffin MD; Serindoux J; Gay Y; Fischer S; Sterle S; Kropp A; Burns CJ; Ernst M; Buchert M; Lucet IS
Structure; 2016 Sep; 24(9):1550-61. PubMed ID: 27545623
[TBL] [Abstract][Full Text] [Related]
6. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a selective inhibitor of doublecortin like kinase 1.
Ferguson FM; Nabet B; Raghavan S; Liu Y; Leggett AL; Kuljanin M; Kalekar RL; Yang A; He S; Wang J; Ng RWS; Sulahian R; Li L; Poulin EJ; Huang L; Koren J; Dieguez-Martinez N; Espinosa S; Zeng Z; Corona CR; Vasta JD; Ohi R; Sim T; Kim ND; Harshbarger W; Lizcano JM; Robers MB; Muthaswamy S; Lin CY; Look AT; Haigis KM; Mancias JD; Wolpin BM; Aguirre AJ; Hahn WC; Westover KD; Gray NS
Nat Chem Biol; 2020 Jun; 16(6):635-643. PubMed ID: 32251410
[TBL] [Abstract][Full Text] [Related]
8. DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells.
Liu H; Wen T; Zhou Y; Fan X; Du T; Gao T; Li L; Liu J; Yang L; Yao J; Ge Y; An G
Biomed Res Int; 2019; 2019():1061979. PubMed ID: 31223610
[TBL] [Abstract][Full Text] [Related]
9. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
10. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics.
Cheng L; Huang S; Chen L; Dong X; Zhang L; Wu C; Ye K; Shao F; Zhu Z; Thorne RF
Curr Med Chem; 2022; 29(13):2261-2273. PubMed ID: 34254905
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.
Wu X; Ruan Y; Jiang H; Xu C
Int J Biochem Cell Biol; 2017 Apr; 85():66-74. PubMed ID: 28161486
[TBL] [Abstract][Full Text] [Related]
12. DCLK1 Expression and its Functional Significance in Intrahepatic Cholangiocarcinoma and Bil-IN Stage.
Fukushima NM; Adachi T; Tanaka T; Matsushima H; Imamura H; Hara T; Soyama A; Hidaka M; Kanetaka K; Eguchi S
Anticancer Res; 2024 Jun; 44(6):2417-2424. PubMed ID: 38821583
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of Inhibition of DCLK1 by Ruxolitinib.
Jang DM; Lim HJ; Hahn H; Lee Y; Kim HK; Kim HS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445192
[TBL] [Abstract][Full Text] [Related]
14. DCLK1 promotes malignant progression of breast cancer by regulating Wnt/β-Catenin signaling pathway.
Wang YL; Li Y; Ma YG; Wu WY
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9489-9498. PubMed ID: 31773701
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
Ali N; Chandrakesan P; Nguyen CB; Husain S; Gillaspy AF; Huycke M; Berry WL; May R; Qu D; Weygant N; Sureban SM; Bronze MS; Dhanasekaran DN; Houchen CW
Oncotarget; 2015 Aug; 6(24):20327-44. PubMed ID: 25948779
[TBL] [Abstract][Full Text] [Related]
16. Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1/STAT3 signaling pathway.
Ye Q; Zhu Y; Shi M; Lv L; Gong Y; Zhang L; Yang L; Zhao H; Zhao C; Xu H
Chin J Nat Med; 2024 Apr; 22(4):318-328. PubMed ID: 38658095
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.
Moore LL; Houchen CW
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003596
[TBL] [Abstract][Full Text] [Related]
18. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer.
Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D
Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103
[TBL] [Abstract][Full Text] [Related]
19. Role of DCLK1 in oncogenic signaling (Review).
Lu Q; Feng H; Chen H; Weygant N; Du J; Yan Z; Cao Z
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36148883
[TBL] [Abstract][Full Text] [Related]
20. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
Wang J; Wang S; Zhou J; Qian Q
Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
